Moody Aldrich Partners LLC Esperion Therapeutics, Inc. Transaction History

Moody Aldrich Partners LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 10, 2021	SELL	$25.12 - $36.89 $1.56 Million - $2.3 Million	-62,245 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$24.2 - $35.76 $940,266 - $1.39 Million	-38,854 Reduced 38.43%	62,245 $1.62 Million
Q3 2020 Nov 12, 2020	SELL	$31.18 - $52.71 $62 - $105	-2 Reduced -0.0%	101,099 $3.76 Million
Q2 2020 Jul 30, 2020	BUY	$30.04 - $51.31 $370,723 - $633,216	12,341 Added 13.9%	101,101 $5.19 Million
Q1 2020 May 07, 2020	SELL	$27.44 - $73.84 $973,324 - $2.62 Million	-35,471 Reduced 28.55%	88,760 $2.8 Million
Q4 2019 Feb 07, 2020	BUY	$35.4 - $59.82 $4.4 Million - $7.43 Million	124,231 New	124,231 $7.41 Million
Q2 2018 Aug 13, 2018	SELL	$36.2 - $76.4 $813,703 - $1.72 Million	-22,478 Closed	0 $0
Q1 2018 Apr 26, 2018	BUY	$65.94 - $80.76 $735,296 - $900,554	11,151 Added 98.45%	22,478 $1.63 Million
Q4 2017 Jan 31, 2018	BUY	$43.47 - $67.43 $102,024 - $158,258	2,347 Added 26.14%	11,327 $746,000
Q3 2017 Nov 13, 2017	BUY	$43.8 - $52.77 $393,324 - $473,874	8,980	8,980 $450,000

207

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $168M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Moody Aldrich Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Moody Aldrich Partners LLC with notifications on news.